Vascular targeting therapies for treatment of malignant disease [1] (multiple letters)

Cancer

Volumn 104, Issue 1, 2005, Pages 216-217

  Brown, Stephen L ^a   Kolozsvary, Andrew ^a   Kim, Jae Ho ^a   Siemann, Dietmar W ^b   Chaplin, David J ^c   Horsman, Michael R ^d  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Oxigene Inc   (United States)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; VASCULAR TARGETING AGENT;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HEMOSTASIS; HUMAN; LETTER; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ARSENICALS; CLINICAL TRIALS; HUMANS; NEOPLASMS; OXIDES;

EID: 20544459602     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21120     Document Type: Letter

References (0)